TY - JOUR
T1 - Hydrofiber dressing with silver for the management of split-thickness donor sites
T2 - A randomized evaluation of two protocols of care
AU - Blome-Eberwein, S.
AU - Johnson, R. M.
AU - Miller, S. F.
AU - Caruso, D. M.
AU - Jordan, M. H.
AU - Milner, S.
AU - Tredget, E. E.
AU - Sittig, K. M.
AU - Smith, L.
N1 - Funding Information:
This study was supported by ConvaTec, a division of ER Squibb & Sons, L.L.C. The study sponsor contributed to the study design and the analysis and interpretation of data. Jo Ann Ottino provided assistance with statistical analyses. Donalyn Hyland and Jonathan N. Latham provided editorial assistance with the preparation of the manuscript.
PY - 2010/8
Y1 - 2010/8
N2 - Background: This randomized, open-label study evaluated Aquacel Ag® Hydrofiber® dressing with silver (HDS; ConvaTec, Skillman, NJ, USA) with an adherent or gelled protocol in the management of split-thickness donor sites. Methods: HDS was the primary dressing in the adherent group (gauze as secondary covering) and gelled group (transparent film as secondary covering). Dressings were changed on study day 1 or 2 and study days 5 (optional), 10 (optional), and 14. The primary outcome was healing (≥90% re-epithelialization) at study day 14. Results: Seventy subjects were treated (36 adherent, 34 gelled). By study day 14, 77% of donor sites had healed (67% adherent, 88% gelled). Pain scores decreased over time in both treatment groups. Investigators were "very satisfied" or "satisfied" with (adherent, gelled) time required to manage dressing change (89%, 79% of subjects), minimization of donor-site pain (64%, 82%), ease of application (97%, 94%), management of drainage (92%, 82%), ease of removal (77%, 85%), and ability of dressing to remain in place (69%, 76%). Thirty-nine (56%) subjects had adverse events, most commonly non-donor-site infection (11%) and gastrointestinal events (11%). Conclusion: In this randomized, open-label study, HDS was well-tolerated, versatile, and effective in the management of split-thickness donor sites.
AB - Background: This randomized, open-label study evaluated Aquacel Ag® Hydrofiber® dressing with silver (HDS; ConvaTec, Skillman, NJ, USA) with an adherent or gelled protocol in the management of split-thickness donor sites. Methods: HDS was the primary dressing in the adherent group (gauze as secondary covering) and gelled group (transparent film as secondary covering). Dressings were changed on study day 1 or 2 and study days 5 (optional), 10 (optional), and 14. The primary outcome was healing (≥90% re-epithelialization) at study day 14. Results: Seventy subjects were treated (36 adherent, 34 gelled). By study day 14, 77% of donor sites had healed (67% adherent, 88% gelled). Pain scores decreased over time in both treatment groups. Investigators were "very satisfied" or "satisfied" with (adherent, gelled) time required to manage dressing change (89%, 79% of subjects), minimization of donor-site pain (64%, 82%), ease of application (97%, 94%), management of drainage (92%, 82%), ease of removal (77%, 85%), and ability of dressing to remain in place (69%, 76%). Thirty-nine (56%) subjects had adverse events, most commonly non-donor-site infection (11%) and gastrointestinal events (11%). Conclusion: In this randomized, open-label study, HDS was well-tolerated, versatile, and effective in the management of split-thickness donor sites.
KW - Donor site
KW - Healing
KW - Hydrofiber dressing with silver
KW - Pain
UR - http://www.scopus.com/inward/record.url?scp=77953123411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953123411&partnerID=8YFLogxK
U2 - 10.1016/j.burns.2009.06.193
DO - 10.1016/j.burns.2009.06.193
M3 - Article
C2 - 19969423
AN - SCOPUS:77953123411
SN - 0305-4179
VL - 36
SP - 665
EP - 672
JO - Burns
JF - Burns
IS - 5
ER -